{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T02:08:54Z","timestamp":1775873334665,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s13555-016-0163-0","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T08:50:05Z","timestamp":1482310205000},"page":"133-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0552-106X","authenticated-orcid":false,"given":"Franky","family":"Chandra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dendi","family":"Sandiono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Unwati","family":"Sugiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oki","family":"Suwarsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendra","family":"Gunawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,21]]},"reference":[{"key":"163_CR1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrclinonc.2011.192","volume":"9","author":"DMK Keefe","year":"2012","unstructured":"Keefe DMK, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol. 2012;9:98\u2013109.","journal-title":"Nat Rev Clin Oncol."},{"key":"163_CR2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.rmed.2004.08.009","volume":"99","author":"M Reck","year":"2005","unstructured":"Reck M, Gatzemeier U. Gefitinib (\u2018Iressa\u2019):a new therapy for advanced non-small-cell lung cancer. Respir Med. 2005;99:298\u2013307.","journal-title":"Respir Med"},{"key":"163_CR3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2466-12-77","volume":"12","author":"ME Heuvers","year":"2012","unstructured":"Heuvers ME, Hegmans JP, Stricker BH, Aerts JG. Improving lung cancer survival;time to move on. BMC Pulm Med. 2012;12:77\u201381.","journal-title":"BMC Pulm Med."},{"key":"163_CR4","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","volume":"359","author":"RS Herbst","year":"2008","unstructured":"Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367\u201380.","journal-title":"N Engl J Med"},{"issue":"3","key":"163_CR5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1590\/S0365-05962011000300010","volume":"86","author":"F Santiago","year":"2011","unstructured":"Santiago F, Reis JP, Gon\u00e7alo M, Figueiredo A. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors-a study of 14 patients. An Bras Dermatol. 2011;86(3):483\u201390.","journal-title":"An Bras Dermatol."},{"issue":"2","key":"163_CR6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1188\/08.CJON.283-290","volume":"12","author":"B Eaby","year":"2008","unstructured":"Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs. 2008;12(2):283\u201390.","journal-title":"Clin J Oncol Nurs."},{"key":"163_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2009\/849051","volume":"30","author":"M Giovanini","year":"2009","unstructured":"Giovanini M, et al. Clinical significance of skin toxicity due to EGFR-targeted therapies. J Oncol. 2009;30:1\u20138.","journal-title":"J Oncol."},{"key":"163_CR8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2174\/1874375700802010106","volume":"2","author":"H Kitamura","year":"2008","unstructured":"Kitamura H, Yazawa T, Okudela K, Shimoyamada H, Sato H. Molecular and genetic pathogenesis of lung cancer:differences between small-cell and non-small-cell carcinomas. Open Pathol J. 2008;2:106\u201314.","journal-title":"Open Pathol J."},{"issue":"3","key":"163_CR9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3349\/ymj.2006.47.3.293","volume":"47","author":"SH Lee","year":"2006","unstructured":"Lee SH, Jeong SK, Ahn SK. An update of the defensive barrier function of skin. Yonsei Med J. 2006;47(3):293\u2013306.","journal-title":"Yonsei Med J"},{"key":"163_CR10","first-page":"10","volume":"24","author":"A Diaz","year":"2007","unstructured":"Diaz A, Lage A. Therapies based on inhibitors of the epidermal growth factor receptor:reaching for the future. Biotecnol Apl. 2007;24:10\u20138.","journal-title":"Biotecnol Apl."},{"key":"163_CR11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","volume":"58","author":"N Heidary","year":"2008","unstructured":"Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin:an update. J Am Acad Dermatol. 2008;58:545\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"23","key":"163_CR12","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1158\/1078-0432.CCR-05-1247","volume":"11","author":"EEW Cohen","year":"2005","unstructured":"Cohen EEW, et al. Phase II trial of gefitinib 250\u00a0mg daily in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11(23):8418\u201324.","journal-title":"Clin Cancer Res"},{"key":"163_CR13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","volume":"12","author":"TJ Lynch","year":"2007","unstructured":"Lynch TJ, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncol. 2007;12:610\u201321.","journal-title":"Oncol."},{"key":"163_CR14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803\u201312.","journal-title":"Nat Rev Cancer"},{"key":"163_CR15","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","volume":"23","author":"B Burtness","year":"2005","unstructured":"Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebocompared with cisplatin plus cetuximab in metastatic recurrent head and neck cancer: an eastern cooperative oncology group study. J Clin Oncol. 2005;23:8646\u201354.","journal-title":"J Clin Oncol"},{"key":"163_CR16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2133.2009.09536.x","volume":"162","author":"SS Han","year":"2010","unstructured":"Han SS, et al. Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. Br J Dermatol. 2010;162:371\u20139.","journal-title":"Br J Dermatol."},{"key":"163_CR17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.dsi.2011.02.003","volume":"29","author":"S Wang","year":"2011","unstructured":"Wang S, et al. Skin manifestations of gefitinib and the association with survival of advanced non-small-cell lung cancer in Taiwan. Dermatol Sin. 2011;29:13\u20138.","journal-title":"Dermatol Sin."},{"key":"163_CR18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4137\/CMO.S7340","volume":"6","author":"T Araki","year":"2012","unstructured":"Araki T, et al. Review of the treatment of non-small cell lung cancer with gefitinib. Clin Med Insight:Oncol. 2012;6:407\u201321.","journal-title":"Clin Med Insight:Oncol."},{"key":"163_CR19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1473-2165.2007.00300.x","volume":"6","author":"S Verdier-S\u00e9vrain","year":"2007","unstructured":"Verdier-S\u00e9vrain S, Bont\u00e9 F. Skin hydration:a review on its molecular mechanisms. J Cosmet Dermatol. 2007;6:75\u201382.","journal-title":"J Cosmet Dermatol."},{"key":"163_CR20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","volume":"55","author":"E Roe","year":"2006","unstructured":"Roe E, et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol. 2006;55:429\u201337.","journal-title":"J Am Acad Dermatol."},{"key":"163_CR21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.suponc.2010.10.003","volume":"8","author":"Y Balagula","year":"2010","unstructured":"Balagula Y, Lacouture ME, Cotliar JA. Dermatologic toxicities of targeted anticancer therapies. J Support Oncol. 2010;8:149\u201361.","journal-title":"J Support Oncol."},{"key":"163_CR22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1191\/1078155203jp115oa","volume":"9","author":"SR Shah","year":"2003","unstructured":"Shah SR, Walsh TL, Williams CB, Soefje SA. Gefitinib (ZD1839, Iressa\u00ae):a selective epidermal growth factor receptor-tyrosine kinase inhibitor. J Oncol Pharm Pract. 2003;9:151\u201360.","journal-title":"J Oncol Pharm Pract."},{"key":"163_CR23","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.ejca.2010.04.028","volume":"46","author":"E Guttman-Yassky","year":"2010","unstructured":"Guttman-Yassky E, et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer. 2010;46:2010\u20139.","journal-title":"Eur J Cancer"},{"key":"163_CR24","doi-asserted-by":"crossref","unstructured":"Abdullah SE, Haigentz Jr M., Piperdi B. Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management. Dermatol Res Pract. 2012:1\u201310.","DOI":"10.1155\/2012\/351210"},{"issue":"9","key":"163_CR25","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","volume":"16","author":"S Seagert","year":"2005","unstructured":"Seagert S, Custom VE. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16(9):1425\u201333.","journal-title":"Ann Oncol"},{"key":"163_CR26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-9966-31-50","volume":"31","author":"G Fabbrocini","year":"2012","unstructured":"Fabbrocini G, et al. Chemotherapy and skin reactions. J Exp Clin Canc Res. 2012;31:50\u20136.","journal-title":"J Exp Clin Canc Res."},{"key":"163_CR27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/srt.12037","volume":"19","author":"J Plessis","year":"2013","unstructured":"Plessis J. International guidelines for the in vivo assessment of skin properties in non-clinical settings:part 2. Transepidermal water loss and skin hydration. Skin Res Technol. 2013;19:265\u201378.","journal-title":"Skin Res Technol."},{"key":"163_CR28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000088499","volume":"211","author":"U Jacobi","year":"2005","unstructured":"Jacobi U, Gautier J, Sterry W, Lademann J. Gender-related differences in the physiology of the stratum corneum. Dermatology. 2005;211:312\u20137.","journal-title":"Dermatology"},{"key":"163_CR29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000330721","volume":"25","author":"P Kleesz","year":"2012","unstructured":"Kleesz P, Darlenski R, Fluhr JW. Full-body skin mapping for six biophysical parameters: baseline values at 16 anatomical sites in 125 human subjects. Skin Pharmacol Physiol. 2012;25:25\u201333.","journal-title":"Skin Pharmacol Physiol."},{"key":"163_CR30","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/archderm.1995.01690220040008","volume":"131","author":"JT Reed","year":"1995","unstructured":"Reed JT, Ghadially R, Elias PM. Skin type, but neither race nor gender, influence epidermal permeability barrier function. Arch Dermatol. 1995;131:1134\u20138.","journal-title":"Arch Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-016-0163-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T02:27:57Z","timestamp":1498357677000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-016-0163-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,21]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["163"],"URL":"https:\/\/doi.org\/10.1007\/s13555-016-0163-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,21]]}}}